Soligenix, Inc. - Investor Summit Group

Soligenix, Inc.

Ticker

SNGX

Website

Sector

Biotech, Healthcare

Tearsheet

Why Invest

Submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing authorization of HyBryte™ (SGX301 or synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL); • initiation of a Phase 2 clinical trial in mild-to-moderate psoriasis with SGX302 (synthetic hypericin), where we have already validated the biologic activity of synthetic hypericin in CTCL and previously demonstrated positive proof of concept (PoC) in a small Phase 1/2 pilot study in psoriasis; • pursuit of potential opportunities with dusquetide, the active ingredient in SGX942 that demonstrated biological efficacy in the per protocol population in our Phase 3 clinical study in oral mucositis in head and neck cancer (HNC), and potential anti-tumor efficacy in multiple preclinical xenograft studies; • advancing our heat stable vaccine platform technology, including development of filovirus vaccine candidates (targeting Ebola, Sudan, and Marburg Viruses), a novel heat stable COVID-19 (Coronavirus Disease 2019) vaccine candidate, CiVax™, and a ricin toxin vaccine, RiVax®, where non-human primate (NHP) data for all three vaccine programs has demonstrated significant efficacy; and